Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 0.70 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080470 | 0.92 | ALOX5 (0.82) | ALOX5HPGDNOD1NOD2KDM4E | |
| SCHEMBL15275058 | 0.84 | ALOX5 (0.81) | ALOX5HPGDNOD1NOD2KDM4E | |
| SCHEMBL4078770 | 0.84 | ALOX5 (0.81) | ALOX5HPGDNOD1NOD2KDM4E | |
| SCHEMBL4078102 | 0.83 | ALOX5 (0.68) | ALOX5HPGDNOD1KDM4ESMN1; SMN2 | |
| SCHEMBL4083429 | 0.82 | ALOX5 (0.68) | ALOX5HPGDKDM4ESMN1; SMN2CA12 | |
| Setileuton SCHEMBL13691961 | 0.82 | ALOX5 (1.00) | ALOX5HPGDKDM4EALDH1A1LMNA | |
| Setileuton SCHEMBL29371714 | 0.82 | ALOX5 (1.00) | ALOX5HPGDKDM4EALDH1A1LMNA | |
| Setileuton SCHEMBL1528740 | 0.82 | ALOX5 (1.00) | ALOX5HPGDKDM4EALDH1A1LMNA | |
| Setileuton SCHEMBL1528741 | 0.82 | ALOX5 (1.00) | ALOX5HPGDKDM4EALDH1A1LMNA | |
| SCHEMBL4080699 | 0.82 | ALOX5 (0.55) | ALOX5LIPGHPGDNOD1NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030048-A1 | Novel pharmaceutical compounds | BLOUIN MARC | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030048-A1 | Novel pharmaceutical compounds | LTA4H, LTB4R2, LTC4S | ALOX5 12/4885LIPG 134/4885HPGD 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.